Gw Pharma ADR (GWPH) 89.14 $GWPH
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)
Will Medical Marijuana Take Biotech Stocks To A New High?
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it's time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.
XXII: 0.83 (-0.01), GWPH: 89.14 (+0.57)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 0.83 (-0.01), CARA: 5.07 (+0.18), GWPH: 89.14 (+0.57)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 0.83 (-0.01), CARA: 5.07 (+0.18), GWPH: 89.14 (+0.57)
GW Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 6:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference to be held at Terranea in Rancho Palos Verdes, California on 8 June, 2016 at 8:40 a.m. PDT and at the Jefferies 2016 Global Healthcare Conference at the Grand Hyatt Hotel in New York City on 9 June, 2016 at 4:00 p.m. EDT.
GWPH: 89.14 (+0.57)
By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement
PR Newswire - Wed May 25, 7:30AM CDT
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
INSY: 13.07 (+0.29), GWPH: 89.14 (+0.57)
ALEXRODNEWS.COM Covers It's April Feature Short PNPL For 721% ROI; Covers Profitable GWPH, MSRT, Initiates Long in BANC AND MGT
ACCESSWIRE - Tue May 17, 8:28AM CDT
LOS ANGELES, CA / ACCESSWIRE / May 17, 2016 / Axelrodnews.com, a leading investment newsletter that covers stocks for both long and short opportunities, today updated its research and takes profits on recently initiated short positions in PNPL, GWPH, MSRT, and is initiating coverage on two new long opinions: BANC and MGT.
GWPH: 89.14 (+0.57), MGT: 3.20 (+0.19), BANC: 19.60 (+0.35)
Industrial Hemp Producing Solid Revenue Opportunities for Cannabis & Agriculture Industries; Company Announces Product Sales of Raw Kenaf
PR Newswire - Mon May 16, 9:20AM CDT
The Cannabis industry's applications continue to grow with the increasing demand for hemp-based and other natural fiber composite products. U.S. consumers are likely to find kenaf fiber in carpet backing and padding, a fiber mat in automobiles, biofuels applications while the US government is starting to recognize the difference between marijuana and hemp. Legislation is being passed in many states to allow industrial hemp with a THC content of 0.3% or less to be grown in research studies.
GWPH: 89.14 (+0.57)
GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May
GlobeNewswire - Mon May 16, 6:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or "the Company", a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.
GWPH: 89.14 (+0.57)
The Cannabis Industry Takes a Step Forward in 2016
PR Newswire - Tue May 10, 8:15AM CDT
The Cannabis industry had a major victory last week, without even appearing in court. The US Department of Justice, after four years, has dropped the case to shut down Harborside Health Center in Oakland, California, which is currently the largest marijuana dispensary in the United States.
GWPH: 89.14 (+0.57)
GW Pharmaceuticals (GWPH) Q2 Loss Lower than Expected
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:02AM CDT
GW Pharmaceuticals (GWPH) reported a narrower-than-expected second-quarter fiscal 2016 loss of $1.10 per share.
VTL: 7.11 (+0.23), GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01)
GW Pharma (GWPH) Posts Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:18AM CDT
GW Pharma reported narrower-than-expected second-quarter loss.
GWPH: 89.14 (+0.57)
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
GlobeNewswire - Thu May 05, 6:01AM CDT
- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome -
GWPH: 89.14 (+0.57)
Market Briefing: Cannabis Market Reaches New Heights
PR Newswire - Wed May 04, 4:07PM CDT
It is a rare opportunity when a market that is potentially worth hundreds of billions of dollars is virtually untouched by large companies. While the number of states where the growth and sales of Cannabis products remains limited, the majority of the population in the United States approves the end of federal marijuana prohibition nationwide. For now, in states where cannabis is a legitimate and legal product, sales are through the roof.
GWPH: 89.14 (+0.57)
Investor Calendar Invites You to the GW Pharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 5, 2016
ACCESSWIRE - Wed May 04, 3:10PM CDT
LONDON, ENGLAND / ACCESSWIRE / May 4, 2016 / GW Pharmaceuticals plc (NASDAQ: GWPH) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, May 5, 2016 at 9:00 AM Eastern Time.
GWPH: 89.14 (+0.57)
The Cannabis Market Reaches New Heights
PR Newswire - Wed May 04, 2:18PM CDT
It is a rare opportunity when a market that is potentially worth hundreds of billions of dollars is virtually untouched by large companies. While the number of states where the growth and sales of Cannabis products remains limited, the majority of the population in the United States approves the end of federal marijuana prohibition nationwide. For now, in states where cannabis is a legitimate and legal product, sales are through the roof.
GWPH: 89.14 (+0.57)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 39.63 (+0.89), BIIB: 238.62 (+4.02), CNAT: 2.13 (+0.09), AMGN: 152.27 (+2.46), RPRX: 1.70 (+0.07), JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92), GWPH: 89.14 (+0.57), GERN: 2.75 (+0.08), AVEO: 0.98 (-0.01), ICPT: 154.26 (+6.16), AGIO: 48.50 (+1.43), NVS: 80.67 (+0.96)
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May
GlobeNewswire - Wed May 04, 6:02AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company", a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.
GWPH: 89.14 (+0.57)
What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:45PM CDT
GW Pharmaceuticals (GWPH), which is set to report second-quarter fiscal 2016 results on May 5, had posted a positive surprise of 34.78%.
ZTS: 47.90 (+0.57), IPXL: 30.33 (+0.81), GWPH: 89.14 (+0.57), JAZZ: 145.00 (+2.06)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), BMY: 72.64 (+0.33)
Will Medical Marijuana Take Biotech Stocks To A New High?
ACCESSWIRE - Wed Jun 22, 7:16AM CDT
WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it's time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.
XXII: 0.83 (-0.01), GWPH: 89.14 (+0.57)
NTRR: Cannabis' Better-than-Expected Tax Revenues Could Speed Legalization Efforts
ACCESSWIRE - Wed Jun 08, 4:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 8, 2016 / Legalized cannabis has created tax windfalls for Washington and Colorado, and other states currently on the legalization fence are enviously and eagerly eyeing those results. For Neutra Corp. (OTCQB: NTRR), this scenario could create a positive environment for its cannabis-related business as more and more revenue-hungry states approve the substance for adult recreational use to grab additional tax monies.
XXII: 0.83 (-0.01), CARA: 5.07 (+0.18), GWPH: 89.14 (+0.57)
NTRR Aiming to Acquire Medical Marijuana Facility, Starts Talks on Colorado Sites
ACCESSWIRE - Thu Jun 02, 4:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 2, 2016 / Neutra Corp. (OTCQB: NTRR) is opening discussions on acquiring a 100 percent interest in a medical marijuana dispensary and/or cultivation center in Colorado and has narrowed its focus to several promising and available locations in the Centennial State. The company is also looking over similar facilities in California.
XXII: 0.83 (-0.01), CARA: 5.07 (+0.18), GWPH: 89.14 (+0.57)
GW Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 6:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference to be held at Terranea in Rancho Palos Verdes, California on 8 June, 2016 at 8:40 a.m. PDT and at the Jefferies 2016 Global Healthcare Conference at the Grand Hyatt Hotel in New York City on 9 June, 2016 at 4:00 p.m. EDT. GWPH: 89.14 (+0.57)
By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement
PR Newswire - Wed May 25, 7:30AM CDT
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
INSY: 13.07 (+0.29), GWPH: 89.14 (+0.57)
ALEXRODNEWS.COM Covers It's April Feature Short PNPL For 721% ROI; Covers Profitable GWPH, MSRT, Initiates Long in BANC AND MGT
ACCESSWIRE - Tue May 17, 8:28AM CDT
LOS ANGELES, CA / ACCESSWIRE / May 17, 2016 / Axelrodnews.com, a leading investment newsletter that covers stocks for both long and short opportunities, today updated its research and takes profits on recently initiated short positions in PNPL, GWPH, MSRT, and is initiating coverage on two new long opinions: BANC and MGT.
GWPH: 89.14 (+0.57), MGT: 3.20 (+0.19), BANC: 19.60 (+0.35)
Industrial Hemp Producing Solid Revenue Opportunities for Cannabis & Agriculture Industries; Company Announces Product Sales of Raw Kenaf
PR Newswire - Mon May 16, 9:20AM CDT
The Cannabis industry's applications continue to grow with the increasing demand for hemp-based and other natural fiber composite products. U.S. consumers are likely to find kenaf fiber in carpet backing and padding, a fiber mat in automobiles, biofuels applications while the US government is starting to recognize the difference between marijuana and hemp. Legislation is being passed in many states to allow industrial hemp with a THC content of 0.3% or less to be grown in research studies.
GWPH: 89.14 (+0.57)
GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May
GlobeNewswire - Mon May 16, 6:00AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW" or "the Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City. GWPH: 89.14 (+0.57)
The Cannabis Industry Takes a Step Forward in 2016
PR Newswire - Tue May 10, 8:15AM CDT
The Cannabis industry had a major victory last week, without even appearing in court. The US Department of Justice, after four years, has dropped the case to shut down Harborside Health Center in Oakland, California, which is currently the largest marijuana dispensary in the United States.
GWPH: 89.14 (+0.57)
GW Pharmaceuticals (GWPH) Q2 Loss Lower than Expected
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:02AM CDT
GW Pharmaceuticals (GWPH) reported a narrower-than-expected second-quarter fiscal 2016 loss of $1.10 per share.
VTL: 7.11 (+0.23), GWPH: 89.14 (+0.57), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01)
GW Pharma (GWPH) Posts Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:18AM CDT
GW Pharma reported narrower-than-expected second-quarter loss.
GWPH: 89.14 (+0.57)
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
GlobeNewswire - Thu May 05, 6:01AM CDT
- Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome -
GWPH: 89.14 (+0.57)
Market Briefing: Cannabis Market Reaches New Heights
PR Newswire - Wed May 04, 4:07PM CDT
It is a rare opportunity when a market that is potentially worth hundreds of billions of dollars is virtually untouched by large companies. While the number of states where the growth and sales of Cannabis products remains limited, the majority of the population in the United States approves the end of federal marijuana prohibition nationwide. For now, in states where cannabis is a legitimate and legal product, sales are through the roof.
GWPH: 89.14 (+0.57)
Investor Calendar Invites You to the GW Pharmaceuticals Second Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 5, 2016
ACCESSWIRE - Wed May 04, 3:10PM CDT
LONDON, ENGLAND / ACCESSWIRE / May 4, 2016 / GW Pharmaceuticals plc (NASDAQ: GWPH) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, May 5, 2016 at 9:00 AM Eastern Time.
GWPH: 89.14 (+0.57)
The Cannabis Market Reaches New Heights
PR Newswire - Wed May 04, 2:18PM CDT
It is a rare opportunity when a market that is potentially worth hundreds of billions of dollars is virtually untouched by large companies. While the number of states where the growth and sales of Cannabis products remains limited, the majority of the population in the United States approves the end of federal marijuana prohibition nationwide. For now, in states where cannabis is a legitimate and legal product, sales are through the roof.
GWPH: 89.14 (+0.57)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 39.63 (+0.89), BIIB: 238.62 (+4.02), CNAT: 2.13 (+0.09), AMGN: 152.27 (+2.46), RPRX: 1.70 (+0.07), JNJ: 117.38 (+0.92), GILD: 83.37 (+0.92), GWPH: 89.14 (+0.57), GERN: 2.75 (+0.08), AVEO: 0.98 (-0.01), ICPT: 154.26 (+6.16), AGIO: 48.50 (+1.43), NVS: 80.67 (+0.96)
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May
GlobeNewswire - Wed May 04, 6:02AM CDT
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"
, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev. GWPH: 89.14 (+0.57)
What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:45PM CDT
GW Pharmaceuticals (GWPH), which is set to report second-quarter fiscal 2016 results on May 5, had posted a positive surprise of 34.78%.
ZTS: 47.90 (+0.57), IPXL: 30.33 (+0.81), GWPH: 89.14 (+0.57), JAZZ: 145.00 (+2.06)
